Supply, use, and abuse of intravenous immunoglobulin

Current Opinion in Pediatrics

Volumn 11, Issue 6, 1999, Pages 533-539

  Nowak Wegrzyn, Anna ^a,b   Lederman, Howard M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS CHILDREN S CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; BACKACHE; BRAIN DISEASE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SYNTHESIS; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; MYALGIA; NEPHROTOXICITY; PRIORITY JOURNAL; SUBSTITUTION THERAPY; THROMBOEMBOLISM; TOXIC HEPATITIS;

AUTOIMMUNE DISEASES; CHILD; HEMATOLOGIC DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MUCOCUTANEOUS LYMPH NODE SYNDROME; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 0032705402     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199912000-00011     Document Type: Article

References (47)

1. Bresee JS, Mast EE, Coleman PJ, Baron MJ, Sconberger LB, Alter MJ, et al.: Hepatitis C virus infection associated with administration of intravenous immune globulin. JAMA 1996, 276:1563-1567.
2. Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Radaeli E: Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood 1997, 90:1309-1314.
3. Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999, 340:1228-1233.
4. Availability of immune globulin intravenous for treatment of immune deficient patients: United States. MMWR Morb Mortal Wkly Rep 1999, 48:159-162.
5. Schiff RI: Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action. Pediatr Allergy Immunol 1994, 5:63-87 (part I), 5:127-156 (part II).
6. Liese JG, Wintergerst U, Tympner KD, Belohradsky BH: High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992, 146:335-339.
7. Roifman CM, Levinson H, Gelfand EW: High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinemia and chronic lung disease. Lancet 1987, i:1075-1077.
8. Roifman CM, Gelfand EW: Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J 1988, 7:S92-S96.
9. Quartier P, Debre M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al.: Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999, 134:589-596. This paper discusses the outcomes of children with X-linked agammaglobulinemia treated with IVIG early in life. The results emphasize the importance of early diagnosis and treatment in primary immunodeficiency disease.
10. Simoes EAF, Groothuis JR, Tristram DA, Allessi K, Lehr MV, Siber GR, et al.: Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr 1996, 129:214-219.
11. Gaspar J, Jones A: Immunoglobulin replacement therapy by rapid subcutaneous infusion. Arch Dis Child 1998, 79:48-51.
12. Stiehm ER, Casillas AM, Finkelstein JZ, Gallagher KT, Groncy PM, Kobayashi R, et al.: Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol 1998, 10:848-849. This paper reports the experience of successful use of subcutaneous infusion of gamma globulin in eight patients unable to tolerate IVIG. It discusses the advantages of using this alternative route.
13. Chuchjo T, Nakao S, Matsuda T: Successful treatment of persistent erythroid aplasia caused by parvovirus B19 infection in a patient with common variable immunodeficiency with low-dose immunoglobulin. Am J Hematol 1999, 60:222-224.
14. Seyama K, Kobayashi R, Hasle H, Apter AJ, Rutlege JC, Rosen D, et al.: Parvovirus B19-induced anemia as the presenting manifestation of X-linked hyper-IgM syndrome. J Infect Dis 1998, 178:318-324.
15. The National Institute of Child Health and Human Development Intravenous Study Group: Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991, 325:73-80.
16. Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, et al.: A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 1994, 331:1181-1187.
17. Mofenson LM, Yogev R, Korelitz J, Bethel J, Krasinski K, Moye J, et al.: Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. Pediatr Infect Dis J 1998, 17:872-880.
18. Mazer BD, Gelfand EW: An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991, 87:976-983.
19. Landwehr LP, Jeppson JD, Katlan MG, Esterl B, McCormick D, Hamilos DL, et al.: Benefits of high-dose IV immunoglobulin in patients with severe steroid-dependent asthma. Chest 1998, 114:1349-1356.
20. Kishiyama JL, Valacer D, Cunningham-Rundles C, Sperber K, Richmond GW, Abramson S, et al.: A multicenter randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol 1999, 91:126-133.
21. Sigman K, Ghibu F, Sommerville W, Toledano BJ, Bastein Y, Cameron L, et al.: Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 1998, 102:421-427.
22. Spann JD, Leung DYM, Chan MIS, Szefler SJ, Gelfand EW: Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol 1999, 103:421-426.
23. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez WJ, et al.: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993, 329:1524-1530.
24. Simoes EA, Sondheimer HM, Top FH, Meissner HC, Welliver RC, Kramer AA, et al.: Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus in infants and children with congenital heart disease. J Pediatr 1998, 133:492-499.
25. American Academy of Pediatrics: "Respiratory syncytial virus." In Red Book: Report of the Committee on Infectious Diseases, edn 24. Elk Grove Village, IL: American Academy of Pediatrics; 1997:447.
26. The IMPACT Study Group: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus monoclonal antibody prophylaxis. Pediatrics 1998, 102:531-537. This landmark study led to the change in clinical practice standards. It also demonstrates the power of molecular biology to produce chimeric or humanized antibodies that are clinically effective.
27. Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, et al.: Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high-risk infants: a consensus opinion. Pediatr Infect Dis J 1999, 18:223-231.
28. American Academy of Pediatrics Committee on Infectious Disease and Committee on Fetus and Newborn: Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998, 102:1211-1216.
29. Yu Z, Lennon VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune disease. N Engl J Med 1999, 340:227-228.
30. Leung DYM: The immunologic effects of IVIG in Kawasaki Disease. Int Rev Immunol 1989, 5:197-202.
31. Xu C, Poirier B, Van Huyen JP, Lucchiari N, Michael O, Chevalier J, et al.: Modulation of endothelial cell function by normal polyspecific human intavenous immunoglobulins: a possible mechanism of action in vascular disease. Am J Pathol 1998, 153:1257-1266.
32. Terai M, Shulma ST: Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997, 131:888-893.
33. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP: Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998, 17:1144-1148.
34. Blanchette V, Imbach P, Andrew M, Adams, McMillan J, Wang E, et al.: Randomized trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994, 344:703-706.
35. Tarantino MD, Madden RM, Fennwald DL, Patel CC, Bertolone SJ: Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. J Pediatr 1999, 134:21-26.
36. Madeiros D, Buchanan GR: Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr 1998, 133:334-339. This is the first study to provide information about both clinical outcomes (rates of major hemorrhage) and the response to treatment in children with ITP.
37. Fehr J, Hoffman V, Kappeler U: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma-globulin. N Engl J Med 1982, 306:1254-1258.
38. Bussel JB: The use of intravenous gamma-globulin in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 1989, 53(suppl):147-155.
39. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
40. Dalaks MC: Intravenous immune globulin therapy for neurologic disease. Ann intern Med 1997, 126:721-730.
41. Mastaglis FL, Phillips BA, Zilko PJ: Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998, 65:107-110.
42. Burks AW, Sampson HA, Buckley RH: Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med 1986, 314:560-564.
43. Ahsan N: Intravenous immunoglobulin induced nephropathy: a complication of IVIG therapy. J Nephrol 1998, 11:157-161.
44. Stahl M, Schifferli JA: The renal risks of high-dose intravenous immunoglobulin treatment. Nephrol Dial Transplant 1998, 13:2182-2185.
45. Sekul EA, Cupler EJ, Dalakas MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994, 121:259-262.
46. Mathy I, Van Raemdonck F, Delbecq J, Depre A: Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Acta Neurol Belg 1998, 98:347-351.
47. Bolanos-Meade J, Keung YK, Cobos E: Recurrent lymphocytic pleural effusion after intravenous immunoglobulin. Am J Hematol 1999, 60:248-254.